FLORHAM PARK, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that the company will report its financial results for the year ended December 31, 2023, on Wednesday, March 27, 2024. Management will also host a conference call with investors to discuss financial results and provide an overview at 8:30 am Eastern Time. Details for the call are as follows:
| Conference call & Webcast Details: | |
| Date: | Wednesday, March 27 |
| Time: | 8:30 am Eastern Time |
| Toll Free: | 1-888-886-7786 |
| Webcast: | Click HERE |
| Call meTM: | Click HERE |
Participants may use the dial-in numbers above and be answered by an operator OR click the Call meTM link for instant telephone access to the event. The Call meTM link will be made active 15 minutes prior to the scheduled start time.
A replay of the call will be available on Events section of the company’s investor relations website.
About Cellectar Biosciences, Inc.
Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects.
The company’s product pipeline includes lead asset iopofosine I 131, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets.
For more information, please visit www.cellectar.com and www.wmclinicaltrial.com or join the conversation by liking and following us on the company’s social media channels: Twitter, LinkedIn, and Facebook.
Contacts
MEDIA:
Claire LaCagnina
Bliss Bio Health
315-765-1462
This email address is being protected from spambots. You need JavaScript enabled to view it.
INVESTORS:
Chad Kolean
Chief Financial Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$5.08 |
| Daily Change: | 0.04 0.79 |
| Daily Volume: | 71,487 |
| Market Cap: | US$14.530M |
June 05, 2025 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
